Content about Testosterone

October 16, 2012

Natural Products Solutions recently announced the launch of VirMax T Testosterone. As part of that launch, DSN caught up with NPS president and CEO Marty Gallant to discuss men’s health supplements.

AUDIO Q&A: DSN caught up with Marty Gallant, Natural Products Solutions president and CEO, which recently announced the launch of VirMax T Testosterone, to discuss men’s health supplements.

February 3, 2014

The Food and Drug Administration is investigating the risk of stroke, heart attack and death in men taking FDA-approved testosterone products, the agency announced Friday.

SILVER SPRING, Md. — The Food and Drug Administration is investigating the risk of stroke, heart attack and death in men taking FDA-approved testosterone products, the agency announced Friday. 

November 18, 2013

Drug maker Actavis hopes to become the first to market with a generic version of a topical testosterone replacement drug marketed by Eli Lilly, Actavis said.

DUBLIN — Drug maker Actavis hopes to become the first to market with a generic version of a topical testosterone replacement drug marketed by Eli Lilly, Actavis said.

The generic drug maker it filed with the Food and Drug Administration for approval of testosterone topical solution in the 30-mg-per-1.5 mL strength, a generic version of Lilly's Axiron. The drug is used as a replacement therapy for deficient or absent testosterone.

July 25, 2013

Viviscal, a dietary hair growth supplement brand, has announced the debut of its first national direct response television spot.

CHICAGO — Viviscal, a dietary hair growth supplement brand, has announced the debut of its first national direct response television spot.

July 11, 2013

The National Advertising Division recommended that German-American Technologies modify or discontinue certain advertising claims made for the company’s Nitraflex Hyperemia & Testosterone Enhancing dietary supplement.

NEW YORK — The National Advertising Division on Tuesday recommended that GAT (German-American Technologies) modify or discontinue certain advertising claims made for the company’s Nitraflex Hyperemia & Testosterone Enhancing dietary supplement.

June 25, 2013

A new article in Men's Health magazine gives tips on how men can find alternatives to seeing their doctors about health problems, and those alternatives include pharmacists.

NEW YORK — A new article in Men's Health magazine gives tips on how men can find alternatives to seeing their doctors about health problems, and those alternatives include pharmacists.

April 1, 2013

Just a week after the Supreme Court heard the Federal Trade Commission's lawsuit over its deal with AbbVie to sell a generic version of a testosterone-replacement therapy, Actavis is challenging the patent on another strength of the drug.

PARSIPPANY, N.J. — Just a week after the Supreme Court heard the Federal Trade Commission's lawsuit over its deal with AbbVie to sell a generic version of a testosterone-replacement therapy, Actavis is challenging the patent on another strength of the drug.

Actavis said Monday that it had filed with the Food and Drug Administration for approval of testosterone gel in the 1.62% strength. The drug is a generic version of AbbVie's AndroGel 1.62%. The case that went before the Supreme Court on March 25 concerns the 1% strength of AndroGel.

March 15, 2013

The Food and Drug Administration has approved a new pocket-sized packet option for a testosterone-replacement therapy made by AbbVie, the drug maker said Friday.

CHICAGO — The Food and Drug Administration has approved a new pocket-sized packet option for a testosterone-replacement therapy made by AbbVie, the drug maker said Friday.

AbbVie announced the approval of the new version of AndroGel (testosterone) 1.62%, available in a packet containing 40.5 mg of testosterone in 2.5 g of gel and a packet with 20.25 mg of testosterone in 1.25 g of gel. The drug is used to raise testosterone levels in men with low or no testosterone, known as hypogonadism, estimated to affect nearly 14 million men in the United States.

March 5, 2013

Drug maker Actavis is challenging the patent for a drug used to treat testosterone deficiency or absence in men, the company said.

PARSIPPANY, N.J. — Drug maker Actavis is challenging the patent for a drug used to treat testosterone deficiency or absence in men, the company said.

Actavis, formerly known as Watson Pharmaceuticals, said it had filed a regulatory approval application with the Food and Drug Administration for a generic version of Endo Pharmaceuticals' Fortesta (testosterone) gel in the 10 mg-per-0.5 g strength.

February 5, 2013

The Food and Drug Administration has approved a testosterone gel product made by Perrigo, the drug maker said.

ALLEGAN, Mich. — The Food and Drug Administration has approved a testosterone gel product made by Perrigo, the drug maker said Tuesday.

Perrigo announced the approval of the testosterone gel in the 1% strength for the treatment of men with low or no testosterone.

The drug is bioequivalent to AbbVie's AndroGel, which has annual sales of about $705 million, according to Symphony Health.

February 1, 2013

Men taking long-acting medications for chronic pain are almost five times more likely to have low testosterone levels, according to a new study by Kaiser Permanente.

OAKLAND, Calif. — Men taking long-acting medications for chronic pain are almost five times more likely to have low testosterone levels, according to a new study by Kaiser Permanente.

The study, which the healthcare system called the first to show a significant difference in risk between short-acting and long-acting opioids, appeared in The Clinical Journal of Pain.

January 9, 2013

Four-time NBA champion John Salley will be heading here next week to attend the ECRM Vitamin, Diet and Sports Nutrition conference in support of Natural Product Solutions.

SAN ANTONIO, Texas — Four-time NBA champion John Salley will be heading here next week to attend the ECRM Vitamin, Diet and Sports Nutrition conference in support of Natural Product Solutions. 

Salley is NPS' spokesman for VirMax, a line that consists of five supplement products that are formulated to benefit health levels of testosterone, a healthy prostate and other men’s health issues.

January 8, 2013

Abbott Labs has spun off its specialty drug division into a new company called AbbVie, which the new company's leaders heralded Wednesday by ringing the first opening bell of 2013 at the New York Stock Exchange.

NEW YORK — Abbott Labs has spun off its specialty drug division into a new company called AbbVie, which the new company's leaders heralded Wednesday by ringing the first opening bell of 2013 at the New York Stock Exchange.

December 10, 2012

The Food and Drug Administration has approved a new use for a cancer drug made by Johnson & Johnson, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new use for a cancer drug made by Johnson & Johnson, the agency said Monday.

The FDA announced the approval of Zytiga (abiraterone acetate), made by J&J subsidiary Janssen Biotech, for men with castration-resistant prostate cancer that has spread to other parts of the body, for use prior to receiving chemotherapy. The drug was already approved for castration-resistant prostate cancer in men who had already undergone chemotherapy treatment.

November 5, 2012

Natural Products Solutions recently announced the launch of VirMax T Testosterone. As part of that launch, DSN caught up with NPS president and CEO Marty Gallant to discuss men’s health supplements. 


Natural Products Solutions recently announced the launch of VirMax T Testosterone. As part of that launch, DSN caught up with NPS president and CEO Marty Gallant to discuss men’s health supplements. 


DSN: Men aren’t too proactive addressing their own health issues. How do you market to them?


September 27, 2012

Natural Products Solutions recently announced the launch of VirMax T testosterone booster as the newest addition to the VirMax line of supplements.

TIMONIUM, Md. — Natural Products Solutions recently announced the launch of VirMax T testosterone booster as the newest addition to the VirMax line of supplements. VirMax T made its official debut in early October at the 2012 National Association of Convenience Stores in Las Vegas and it currently is available in Circle K stores nationwide and on Walgreens' Drugstore.com site.

September 4, 2012

The Food and Drug Administration has approved a new drug made by Astellas Pharma U.S. and Medivation for treating prostate cancer, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Astellas Pharma U.S. and Medivation for treating prostate cancer, the agency said Friday.

The FDA announced the approval of Xtandi (enzalutamide) for castration-resistant prostate cancer that has spread or recurred despite medical or surgical therapy to minimize testosterone.

May 21, 2012

The U.S. subsidiary of British drug maker GlaxoSmithKline and U.S.-based Auxilium Pharmaceuticals will co-promote a testosterone-replacement drug, the two said Monday.

MALVERN, Pa. — The U.S. subsidiary of British drug maker GlaxoSmithKline and U.S.-based Auxilium Pharmaceuticals will co-promote a testosterone-replacement drug, the two said Monday.

GSK and Auxilium announced an agreement for the co-promotion of Testim 1% (testosterone gel), used in men with conditions related to deficiency or absence of the hormone.

November 2, 2011

Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

ALLEGAN, Mich. — Drug maker Perrigo has filed for regulatory approval of a generic topical drug for treating testosterone deficiency, prompting a patent infringement suit from the branded version's manufacturer.

October 21, 2011

The Food and Drug Administration has approved a new formulation of a testosterone therapy made by Watson Pharmaceuticals, the drug maker said Friday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a new formulation of a testosterone therapy made by Watson Pharmaceuticals, the drug maker said Friday.

Watson announced the approval of its Androderm (testosterone) transdermal system in the 2-mg and 4-mg formulation. The company said the new smaller size and lower-dose patch would provide "highly effective" testosterone administration with a 20% reduction in the active ingredient from the original strength. Watson plans to launch the new patch next month.

June 29, 2011

A topical drug made by Eli Lilly restored testosterone to normal levels in men with abnormally low testosterone, according to results of a late-stage clinical trial.

INDIANAPOLIS — A topical drug made by Eli Lilly restored testosterone to normal levels in men with abnormally low testosterone, according to results of a late-stage clinical trial.

Lilly announced results of a phase-3 trial of Axiron (testosterone) topical solution, a treatment for the condition, also known as hypogonadism. Study results also showed that the drug improved symptoms associated with it.

Hypogonadism results from damage or disease of the testicles, hypothalamus or pituitary glands that inhibits production of testosterone.

June 13, 2011

Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

BOSTON — Men with prostate cancer are at a higher risk of developing diabetes or diabetes risk factors if they receive a therapy designed to block the production of testosterone, a new study has suggested.

May 2, 2011

The Food and Drug Administration has approved a treatment made by Abbott for low testosterone in men, the drug maker said Friday.

ABBOTT PARK, Ill. — The Food and Drug Administration has approved a treatment made by Abbott for low testosterone in men, the drug maker said Friday.

Abbott announced the approval of AndroGel (testosterone gel) in the 1.62% strength, a clear, odorless topical gel for men with hypogonadism. The company already markets AndroGel in the 1% strength.

The new gel contains 40.5 mg of testosterone in two pump presses, while AndroGel 1% contains 50 mg in four pump presses, but the company said the two were not interchangeable.

April 13, 2011

The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

LINCOLNSHIRE, Ill. — The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

The two companies said the FDA had accepted their application for Bio-T-Gel and expected to complete its review by mid-November.

April 4, 2011

A topical medication for treating low testosterone in men now is available, drug maker Eli Lilly said.

INDIANAPOLIS — A topical medication for treating low testosterone in men now is available, drug maker Eli Lilly said.

Lilly announced the availability of Axiron (testosterone), a topical solution designed for application under the arm.

The Food and Drug Administration approved Axiron in November, making it the only testosterone replacement therapy applied to the underarm.